Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Zytiga (abiraterone acetate) – Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Drug (Brand/Generic)

Zytiga / abiraterone acetate

Company/Licensee

BTG/Johnson & Johnson

Therapy Class

Hormonal therapy

Product Description

Androgen inhibitor

Current Indication

Metastatic prostate cancer

Market Sector

Oncology

Development Status

Approved in US
Expand
Close
Close
Close

Go Top